Subject(s)
Collagen Type IV/genetics , Hydranencephaly/genetics , Mutation/genetics , Cerebellar Diseases/diagnosis , Cerebellar Diseases/diagnostic imaging , Cerebellar Diseases/genetics , Cerebellum/abnormalities , Cerebellum/diagnostic imaging , Cerebral Hemorrhage/diagnostic imaging , Cerebral Hemorrhage/genetics , Child, Preschool , Diagnosis, Differential , Fatal Outcome , Female , Humans , Hydranencephaly/diagnosis , Hydranencephaly/diagnostic imaging , Infant , Infant, Newborn , Male , Porencephaly , Ultrasonography, PrenatalABSTRACT
Derivatives of 4-methylumbelliferone (4MU) are favorite substrates for the measurement of lysosomal enzyme activities in a wide variety of cell and tissue specimens. Hydrolysis of these artificial substrates at acidic pH leads to the formation of 4-methylumbelliferone, which is highly fluorescent at a pH above 10. When used for the assay of enzyme activities in dried blood spots the light emission signal can be very low due to the small sample size so that the patient and control ranges are not widely separated. We have investigated the hypothesis that quenching of the fluorescence by hemoglobin leads to appreciable loss of signal and we show that the precipitation of hemoglobin with trichloroacetic acid prior to the measurement of 4-methylumbelliferone increases the height of the output signal up to eight fold. The modified method provides a clear separation of patients' and controls' ranges for ten different lysosomal enzyme assays in dried blood spots, and approaches the conventional leukocyte assays in outcome quality.
Subject(s)
Hemoglobins/analysis , Hymecromone/analogs & derivatives , Lysosomal Storage Diseases/diagnosis , Adolescent , Adult , Case-Control Studies , Clinical Enzyme Tests , Enzyme Assays , Enzymes/blood , Fluorescence , Fractional Precipitation , Humans , Hymecromone/blood , Hymecromone/chemistry , Indicators and Reagents , Infant , Leukocytes/enzymology , Lysosomal Storage Diseases/blood , Trichloroacetic Acid/chemistryABSTRACT
OBJECTIVE: To investigate body fluids of patients with undiagnosed leukodystrophies using in vitro (1)H-NMR spectroscopy (H-NMRS). METHODS: We conducted a cross-sectional study using high-resolution in vitro H-NMRS on CSF and urine samples. RESULTS: We found a significant increase of free sialic acid in CSF or urine in 6 of 41 patients presenting with hypomyelination of unknown etiology. Molecular genetic testing revealed pathogenic mutations in the SLC17A5 gene in all 6 patients. H-NMRS revealed an increase of N-acetylaspartylglutamate in the CSF of all patients with SLC17A5 mutation (range 13-114 micromol/L, reference <12 micromol/L). CONCLUSION: In patients with undiagnosed leukodystrophies, increased free sialic acid in CSF or urine is a marker for free sialic acid storage disorder and facilitates the identification of the underlying genetic defect. Because increase of N-acetylaspartylglutamate in CSF has been observed in other hypomyelinating disorders, it can be viewed as a marker of a subgroup of hypomyelinating disorders.
Subject(s)
Demyelinating Diseases/cerebrospinal fluid , Dipeptides/cerebrospinal fluid , Organic Anion Transporters/genetics , Sialic Acid Storage Disease/cerebrospinal fluid , Sialic Acid Storage Disease/diagnosis , Symporters/genetics , Child , Child, Preschool , Cross-Sectional Studies , Demyelinating Diseases/etiology , Demyelinating Diseases/urine , Female , Genetic Testing , Genotype , Humans , Infant , Magnetic Resonance Imaging , Magnetic Resonance Spectroscopy , Male , Mutation , N-Acetylneuraminic Acid/cerebrospinal fluid , N-Acetylneuraminic Acid/urine , Sialic Acid Storage Disease/complications , Sialic Acid Storage Disease/genetics , Sialic Acid Storage Disease/urine , Young AdultABSTRACT
In order to identify new metabolic abnormalities in patients with complex neurodegenerative disorders of unknown aetiology, we performed high resolution in vitro proton nuclear magnetic resonance spectroscopy on patient cerebrospinal fluid (CSF) samples. We identified five adult patients, including two sisters, with significantly elevated free sialic acid in the CSF compared to both the cohort of patients with diseases of unknown aetiology (n = 144; P < 0.001) and a control group of patients with well-defined diseases (n = 91; P < 0.001). All five patients displayed cerebellar ataxia, with peripheral neuropathy and cognitive decline or noteworthy behavioural changes. Cerebral MRI showed mild to moderate cerebellar atrophy (5/5) as well as white matter abnormalities in the cerebellum including the peridentate region (4/5), and at the periventricular level (3/5). Two-dimensional gel analyses revealed significant hyposialylation of transferrin in CSF of all patients compared to age-matched controls (P < 0.001)--a finding not present in the CSF of patients with Salla disease, the most common free sialic acid storage disorder. Free sialic acid content was normal in patients' urine and cultured fibroblasts as were plasma glycosylation patterns of transferrin. Analysis of the ganglioside profile in peripheral nerve biopsies of two out of five patients was also normal. Sequencing of four candidate genes in the free sialic acid biosynthetic pathway did not reveal any mutation. We therefore identified a new free sialic acid syndrome in which cerebellar ataxia is the leading symptom. The term CAFSA is suggested (cerebellar ataxia with free sialic acid).
Subject(s)
Cerebellar Ataxia/cerebrospinal fluid , N-Acetylneuraminic Acid/cerebrospinal fluid , Adolescent , Adult , Aged , Aged, 80 and over , Atrophy/cerebrospinal fluid , Cells, Cultured , Cerebellar Ataxia/pathology , Cerebellum/pathology , Child , Child, Preschool , Cohort Studies , Female , Humans , Infant , Magnetic Resonance Imaging/methods , Magnetic Resonance Spectroscopy/methods , Male , Middle Aged , Transferrin/cerebrospinal fluidABSTRACT
Malonyl-CoA decarboxylase (MCD) deficiency is an extremely rare inborn error of metabolism that presents with metabolic acidosis, hypoglycemia, and/or cardiomyopathy. Patients also show neurological signs and symptoms that have been infrequently reported. We describe a girl with MCD deficiency, whose brain MRI shows white matter abnormalities and additionally diffuse pachygyria and periventricular heterotopia, consistent with a malformation of cortical development. MLYCD-gene sequence analysis shows normal genomic sequence but no messenger product, suggesting an abnormality of transcription regulation. Our patient has strikingly low appetite, which is interesting in the light of the proposed role of malonyl-CoA in the regulation of feeding control, but this remains to be confirmed in other patients. Considering the incomplete understanding of the role of metabolic pathways in brain development, patients with MCD deficiency should be evaluated with brain MRI and unexplained malformations of cortical development should be reason for metabolic screening.
Subject(s)
Brain Diseases, Metabolic/genetics , Brain/abnormalities , Carboxy-Lyases/deficiency , Agenesis of Corpus Callosum , Brain Diseases, Metabolic/enzymology , Brain Stem/abnormalities , Carboxy-Lyases/genetics , Cells, Cultured , Cerebellum/abnormalities , Cerebral Cortex/abnormalities , Child, Preschool , DNA Mutational Analysis , Eating/genetics , Female , Fibroblasts/enzymology , Humans , Infant , Infant, Newborn , Magnetic Resonance Imaging , Middle Aged , Skin/cytology , Skin/enzymologyABSTRACT
Lysosomal free sialic acid storage diseases are recessively inherited allelic neurodegenerative disorders that include Salla disease (SD) and infantile sialic acid storage disease (ISSD) caused by mutations in the SLC17A5 gene encoding for a lysosomal membrane protein, sialin, transporting sialic acid from lysosomes. The classical form of SD, enriched in the Finnish population, is related to the p.R39C designed Salla(FIN) founder mutation. A more severe phenotype is due both to compound heterozygosity for the p.R39C mutation and to different mutations. The p.R39C has not been reported in ISSD. We identified the first case of SD caused by the homozygosity for p.K136E (c.406A>G) mutation, showing a severe clinical picture, as demonstrated by the early age at onset, the degree of motor retardation, the occurrence of peripheral nerve involvement, as well as cerebral hypomyelination. Recently, in vitro functional studies have shown that the p.K136E mutant produces a mislocalization and a reduced activity of the intracellular sialin. We discuss the in vivo phenotypic consequence of the p.K136E in relation to the results obtained by the in vitro functional characterization of the p.K136E mutant. The severity of the clinical picture, in comparison with the classical SD, may be explained by the fact that the p.K136E mutation mislocalizes the protein to a greater degree than p.R39C. On the other hand, the presence of a residual transport activity may account for the absence of hepatosplenomegaly, dysostosis multiplex, and early lethality typical of ISSD and related to the abolished transport activity found in this latter form.
Subject(s)
Homozygote , Mutation , Organic Anion Transporters/genetics , Sialic Acid Storage Disease/genetics , Symporters/genetics , Brain/pathology , Child, Preschool , Genotype , Humans , Italy , Lysosomes/metabolism , Magnetic Resonance Imaging , Male , N-Acetylneuraminic Acid/metabolism , PhenotypeABSTRACT
The present study reports two Italian brothers affected by severe Salla disease (sialic acid storage disease), a slowly progressive autosomal recessive neurodegenerative disorder prevalent in the Finnish population. Mutations of the SLC17A5 gene, which encodes a protein called sialin, are the primary cause of both Salla disease and infantile sialic acid storage disease (ISSD), a clinically distinct severe disorder. All Finnish patients with Salla disease show a R39C mutation. Both patients showed moderate intellectual disability, spastic ataxic syndrome, hypomyelination and cerebellar atrophy on magnetic resonance imaging (MRI), and lysosomal storage, all typical of Salla disease. Mutation analysis of the SLC17A5 gene in the younger brother revealed no R39C mutation, but a 15-bp deletion in exon 6 on one of the alleles. This mutation is the same described in French-Canadian patients with ISSD. Salla disease must be suspected in patients with unexplained psychomotor retardation associated with ataxia and/or pyramidal symptoms, and MRI findings consistent with cerebral hypomyelination, irrespective of the patient's ethnic origin. A mutation screening based on R39C change does not exclude Salla disease outside Finland. Conversely, mutations found in ISSD can be expected, even in patients showing the Salla phenotype (e.g. symptoms at the milder end of the spectrum).
Subject(s)
Sialic Acid Storage Disease/genetics , Adolescent , Alleles , Child , DNA Mutational Analysis , Genetic Variation , Humans , Italy , Magnetic Resonance Imaging , Male , Mutation , Psychomotor Disorders , Sequence Deletion , Sialic Acid Storage Disease/diagnosis , Siblings , Skin/pathology , Skin/ultrastructureABSTRACT
In the group of lysosomal storage diseases, transport disorders occupy a special place because they represent rare examples of inborn errors of metabolism caused by a defect of an intracellular membrane transporter. In particular, two disorders are caused by a proven defect in carrier-mediated transport of metabolites: cystinosis and the group of sialic acid storage disorders (SASD). The recent identification of the gene mutations for both disorders will improve patient diagnosis and shed light on new physiological mechanisms of intracellular trafficking.
Subject(s)
Cystinosis/genetics , Mucolipidoses/genetics , Animals , Biological Transport , Cystinosis/metabolism , Humans , Intracellular Membranes/metabolism , Lysosomal Storage Diseases/genetics , Lysosomal Storage Diseases/metabolism , Lysosomes/metabolism , Mucolipidoses/metabolismABSTRACT
Sialic acid storage diseases (SASD, MIM 269920) are autosomal recessive neurodegenerative disorders that may present as a severe infantile form (ISSD) or a slowly progressive adult form, which is prevalent in Finland (Salla disease). The main symptoms are hypotonia, cerebellar ataxia and mental retardation; visceromegaly and coarse features are also present in infantile cases. Progressive cerebellar atrophy and dysmyelination have been documented by magnetic resonance imaging (ref. 4). Enlarged lysosomes are seen on electron microscopic studies and patients excrete large amounts of free sialic acid in urine. A H+/anionic sugar symporter mechanism for sialic acid and glucuronic acid is impaired in lysosomal membranes from Salla and ISSD patients. The locus for Salla disease was assigned to a region of approximately 200 kb on chromosome 6q14-q15 in a linkage study using Finnish families. Salla disease and ISSD were further shown to be allelic disorders. A physical map with P1 and PAC clones was constructed to cover the 200-kb area flanked by the loci D6S280 and D6S1622, providing the basis for precise physical positioning of the gene. Here we describe a new gene, SLC17A5 (also known as AST), encoding a protein (sialin) with a predicted transport function that belongs to a family of anion/cation symporters (ACS). We found a homozygous SLC17A5 mutation (R39C) in five Finnish patients with Salla disease and six different SLC17A5 mutations in six ISSD patients of different ethnic origins. Our observations suggest that mutations in SLC17A5 are the primary cause of lysosomal sialic acid storage diseases.
Subject(s)
Carrier Proteins/genetics , Ion Transport/genetics , Mutation , Neurodegenerative Diseases/genetics , Neurodegenerative Diseases/metabolism , Sialic Acids/metabolism , Adult , Amino Acid Sequence , Anion Transport Proteins , Base Sequence , Carrier Proteins/chemistry , Carrier Proteins/metabolism , DNA Primers/genetics , Female , Gene Expression , Genes, Recessive , Humans , Infant , Male , Models, Molecular , Molecular Sequence Data , Pedigree , RNA, Messenger/genetics , RNA, Messenger/metabolism , Sequence Homology, Amino Acid , Tissue DistributionABSTRACT
Transport of sialic acid through the lysosomal membrane is defective in the human sialic acid storage disease. The mammalian sialic acid carrier has a wide substrate specificity for acidic monosaccharides. Recently, we showed that also non-sugar monocarboxylates like L-lactate are substrates for the carrier. Here we report that other organic anions, which are substrates for carriers belonging to several anion transporter families, are recognized by the sialic acid transporter. Hence, the mammalian system reveals once more novel aspects of solute transport, including sugars and a wide array of non-sugar compounds, apparently unique to this system. These data suggest that the search for the sialic acid storage disease gene can be initiated by a functional selection of genes from a limited number of anion transporter families. Among these, candidates will be identified by mapping to the known sialic acid storage disease locus.
Subject(s)
Carrier Proteins/metabolism , Liver/metabolism , Lysosomes/metabolism , Membrane Proteins/metabolism , N-Acetylneuraminic Acid/metabolism , Nucleotide Transport Proteins , Animals , Anions/metabolism , Biological Transport/genetics , Carrier Proteins/genetics , Humans , Liver/ultrastructure , Lysosomal Storage Diseases/genetics , Membrane Proteins/genetics , Rats , Substrate SpecificityABSTRACT
Sialic acid and glucuronic acid are monocarboxylated monosaccharides, which are normally present in sugar side chains of glycoproteins, glycolipids, and glycosaminoglycans. After degradation of these compounds in lysosomes, the free monosaccharides are released from the lysosome by a specific membrane transport system. This transport system is deficient in the human hereditary lysosomal sialic acid storage diseases (Salla disease and infantile sialic acid storage disease, OMIM 269920). The lysosomal sialic acid transporter from rat liver has now been purified to apparent homogeneity in a reconstitutively active form by a combination of hydroxyapatite, lectin, and ion exchange chromatography. A 57-kDa protein correlated with transport activity. The transporter recognized structurally different types of acidic monosaccharides, like sialic acid, glucuronic acid, and iduronic acid. Transport of glucuronic acid was inhibited by a number of aliphatic monocarboxylates (i.e. lactate, pyruvate, and valproate), substituted monocarboxylates, and several dicarboxylates. cis-Inhibition, trans-stimulation, and competitive inhibition experiments with radiolabeled glucuronic acid as well as radiolabeled L-lactate demonstrated that L-lactate is transported by the lysosomal sialic acid transporter. L-Lactate transport was proton gradient-dependent, saturable with a Km of 0.4 mM, and mediated by a single mechanism. These data show striking biochemical and structural similarities of the lysosomal sialic acid transporter with the known monocarboxylate transporters of the plasma membrane (MCT1, MCT2, MCT3, and Mev).
Subject(s)
Liver/metabolism , Lysosomes/metabolism , Membrane Transport Proteins/isolation & purification , Membrane Transport Proteins/metabolism , Organic Anion Transporters , Plant Lectins , Symporters , Animals , Biological Transport , Carboxylic Acids/metabolism , Cell Fractionation , Chromatography , Chromatography, Affinity , Chromatography, Ion Exchange , Durapatite , Humans , Intracellular Membranes/metabolism , Intracellular Membranes/ultrastructure , Lectins , Lysosomal Storage Diseases/genetics , Lysosomes/ultrastructure , Membrane Transport Proteins/genetics , Monosaccharides/metabolism , Rats , Rats, Wistar , Substrate SpecificityABSTRACT
Lysosomes are thought to play a role in various aspects of heavy metal metabolism. In the present study we demonstrate for the first time the presence of a heavy metal ion transport protein in the lysosomal membrane. Uptake of radioactive silver both in highly purified lysosomal membrane vesicles and in purified intact lysosomes showed the typical kinetics of a carrier-mediated process. This transport was stimulated by ATP hydrolysis, and showed specificity for Ag+, Cu2+, and Cd2+. All biochemical properties of this lysosomal metal ion transporter could classify it as a heavy metal transporting P-type ATPase. Long Evans Cinnamon (LEC) rats, an animal model for the copper transport disorder Wilson disease, showed normal lysosomal silver transport.
Subject(s)
Adenosine Triphosphatases/metabolism , Carrier Proteins/metabolism , Liver/metabolism , Lysosomes/metabolism , Silver/metabolism , Adenosine Triphosphate/metabolism , Animals , Cadmium/metabolism , Cell Fractionation , Copper/metabolism , Intracellular Membranes/metabolism , Kinetics , Rats , Rats, Long-Evans , Rats, Wistar , Ribonucleotides/pharmacology , Substrate SpecificityABSTRACT
Menkes disease is a genetic disorder of copper metabolism. Copper uptake and retention assays on fibroblast or amniotic fluid cell cultures have been used for pre- and postnatal diagnosis. These copper loading tests are complicated by the use of 64Cu, which is not commonly available and has a very short (12.8 hours) physical half life. Besides copper, silver is also a substrate for the bacterial homologue of the Menkes transport protein. We report here that loading tests using radioactive silver (110mAg), instead of copper, can be used for the diagnosis of Menkes disease. 110mAg is commercially available and has a convenient physical half life of 250 days, which makes it suitable for use in diagnostic laboratories. Our studies support the hypothesis that reduction of divalent to monovalent copper is an essential step preceding transport.
Subject(s)
Cation Transport Proteins , Menkes Kinky Hair Syndrome/diagnosis , Recombinant Fusion Proteins , Silver , Adenosine Triphosphatases/genetics , Adenosine Triphosphatases/metabolism , Amniotic Fluid/cytology , Carrier Proteins/genetics , Carrier Proteins/metabolism , Cells, Cultured , Copper/metabolism , Copper-Transporting ATPases , Female , Fibroblasts/metabolism , Humans , Menkes Kinky Hair Syndrome/genetics , Pregnancy , Prenatal Diagnosis , Radioisotopes , Silver/metabolism , Time FactorsABSTRACT
Lysosomal sialidase, which was formerly believed to degrade only water-soluble substrates but not glycolipids, cleaves ganglioside substrates II3NeuNAc-LacCer, IV3NeuNAc, II3NeuNAc-GgOse4Cer, IV3 NeuNAc, II3(NeuNAc)2-GgOse4Cer when these are dispersed either with an appropriate detergent (taurodeoxycholate) or with the sulfatide activator protein, a physiologic lipid solubilizer required for the lysosomal hydrolysis of other glycolipids by water-soluble hydrolases. In the presence of the activator protein, time and protein dependence were linear within wide limits, while the detergent rapidly inactivated the enzyme. The disialo group of the b-series gangliosides was only poorly attacked by the enzyme when the lipids were dispersed with the activator protein, whereas in the presence of the detergent, they were hydrolyzed as fast as terminal sialic acid residues. With the appropriate assay method, significant ganglioside sialidase activity could be demonstrated in the secondary lysosome fraction of normal skin fibroblasts but not of sialidosis fibroblasts. Our results support the notion that there is only one lysosomal sialidase, which degrades both the water-soluble and the membrane-bound sialyl glycoconjugates.
Subject(s)
Gangliosides/metabolism , Lysosomes/enzymology , Neuraminidase/metabolism , Enzyme Activation , Humans , Hydrogen-Ion Concentration , Macromolecular Substances , Osmolar Concentration , Placenta/enzymology , Sulfoglycosphingolipids/metabolism , Time FactorsABSTRACT
A Dutch child with psychomotor retardation, impaired speech, ataxia, sialic acid storage and vacuolized skin fibroblasts and lymphocytes was diagnosed as having free sialic acid storage disease. Slight corneal opacities, pale optic disks at the fundus oculi and vertebral abnormalities, not earlier reported in Salla disease, were peculiar to this case. Free sialic acid was about tenfold increased in urine and cultured fibroblasts, without changes in the glycoconjugate-bound sialic acid pool. A subsequent pregnancy of the patient's mother was monitored by assay of sialic acid in chorionic villi and amniotic fluid. An unaffected foetus was predicted. Sialic acid was also assayed in peripheral blood total leucocytes, and in mononuclear and polymorphonuclear (PMN) leucocyte subpopulations. Each of these leucocyte fractions from the patient showed 10- to 30-fold increase in sialic acid content. The PMN subpopulation provided the most restricted range of control values and showed slightly increased values for the patient's parents. These results suggest that the assay of sialic acid in PMN might be useful for the identification of heterozygotes in sialic acid storage disease. Studies on a larger number of obligate heterozygotes are needed to confirm this observation.
Subject(s)
Genetic Carrier Screening , Lysosomal Storage Diseases/diagnosis , Neutrophils/metabolism , Sialic Acids/metabolism , Ataxia/complications , Child, Preschool , Chorionic Villi/metabolism , Fibroblasts/metabolism , Humans , Intellectual Disability/complications , Lysosomal Storage Diseases/genetics , Lysosomal Storage Diseases/metabolism , Male , N-Acetylneuraminic Acid , Prenatal Diagnosis , Skin/pathologyABSTRACT
Lysosomal membrane vesicles purified from rat liver contain a basal chloride conductance that was enhanced in the presence of ATP, non-hydrolysable ATP-analogs and, to a lesser extent, GTP. Other nucleotides, including AMP, ADP and cAMP, as well as CTP and UTP were not effective. Following fusion of the vesicles with an artificial phosphatidylethanolamine/phosphatidylserine bilayer, we found that ATP gamma S dramatically increased the incidence of 4,4'-diisothiocyanostilbene-2,2'-disulphonic acid (DIDS)-sensitive chloride channels with a unitary slope conductance of approx. 40 pS in 300 mM/50 mM KCl buffers and 120 pS in symmetrical 300 mM KCl buffers. Since similar results were obtained with AMP-PNP, the results indicate that lysosomes contain a chloride permeable ion channel that is activated by ATP through allosteric interaction.
Subject(s)
Intracellular Membranes/metabolism , Liver/ultrastructure , Lysosomes/ultrastructure , Membrane Proteins/metabolism , Nucleotides/pharmacology , 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid , 4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid/analogs & derivatives , 4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid/pharmacology , Adenosine Triphosphate/analogs & derivatives , Adenosine Triphosphate/pharmacology , Animals , Buffers , Chloride Channels , Electric Conductivity , Guanosine Triphosphate/pharmacology , Lipid Bilayers/metabolism , Potassium Chloride/pharmacology , RatsABSTRACT
The lysosomal carrier for the acidic monosaccharides sialic acid and glucuronic acid was solubilized from rat liver lysosomal membranes and reconstituted into phospholipid vesicles. Membrane proteins were extracted from lysosomal membranes with Triton X-100. Upon removal of the detergent by absorption on Amberlite XAD-2 beads, the solubilized proteins were incorporated in egg yolk phospholipids. The reconstituted proteoliposomes show proton-driven carrier-mediated uptake of acidic monosaccharides. The reconstituted carrier was compared in several characteristics with the transporter as present in the native lysosomal membrane. Transporter substrate affinity (Kt for glucuronic acid = 0.4 mM) and specificity for acidic monosaccharides are completely retained. The proteoliposomes also demonstrate trans-stimulation properties with both substrates sialic acid and glucuronic acid. The transporter is inhibited, both in its native and in the reconstituted state, by the sulfhydryl-modifying agents p-chloromercuribenzoic acid, N-ethylmaleimide, and phenyl isothiocyanate. In native membrane vesicles, arginine and histidine modifiers phenylglyoxal and diethyl pyrocarbonate inactivated transport in a substrate-protectable manner. In reconstituted proteoliposomes, similar inhibition was observed. However, protection by substrates was achieved only after treatment with phenylglyoxal. These data suggest that arginine or histidine residues or both are present at or near the substrate binding site of the carrier. Possibly, other essential histidines become exposed in the reconstituted state. The successful functional reconstitution of the lysosomal sialic acid carrier represents an important step towards its purification and its detailed molecular characterization.
Subject(s)
Carrier Proteins/isolation & purification , Lysosomes/metabolism , Sialic Acids/metabolism , Animals , Biological Transport , Carrier Proteins/chemistry , Intracellular Membranes/chemistry , Liver/ultrastructure , Lysosomes/ultrastructure , Proteolipids , RatsABSTRACT
A defective efflux of free sialic acid from the lysosomal compartment has been found in the clinically heterogeneous group of sialic acid storage disorders. Using radiolabeled sialic acid (NeuAc) as a substrate, we have recently detected and characterized a proton-driven carrier for sialic acid in the lysosomal membrane from rat liver. This carrier also recognizes and transports other acidic monosaccharides, among which are uronic acids. If no alternative routes of glucuronic acid transport exist, the disposal of uronic acids can be affected in the sialic acid storage disorders. In this study we excluded the existence of more than one acidic monosaccharide carrier by measuring uptake kinetics of labeled glucuronic acid [( 3H]GlcAc) in rat lysosomal membrane vesicles. [3H]GlcAc uptake was carrier-mediated with an affinity constant of transport (Kt) of 0.3 mM and the transport could be cis-inhibited or trans-stimulated to the same extent by sialic acid or glucuronic acid. Human lysosomal membrane vesicles isolated from cultured fibroblasts showed the existence of a similar proton-driven transporter with the same properties as the rat liver system (Kt of [3H]GlcAc uptake 0.28 mM). Uptake studies with [3H]NeuAc and [3H]GlcAc in resealed lysosome membrane vesicles from cultured fibroblasts of patients with different clinical presentation of sialic acid storage showed defective carrier-mediated transport for both sugars. Further evidence that the defective transport of acidic sugars represents the primary genetic defect in sialic acid storage diseases was provided by the observation of reduced, half-normal transport rates in lymphoblast-derived lysosomal membrane vesicles from five unrelated obligate heterozygotes. This study reports the first observation of a human lysosomal transport defect for multiple physiological compounds.
Subject(s)
Carbohydrate Metabolism, Inborn Errors/metabolism , Lysosomes/metabolism , Sialic Acids/metabolism , Animals , Biological Transport , Cells, Cultured , Glucuronates/metabolism , Glucuronic Acid , Heterozygote , Humans , Hydrogen-Ion Concentration , In Vitro Techniques , Intracellular Membranes/metabolism , Kinetics , Liver/metabolism , RatsABSTRACT
Lysosomal accumulation of free sialic acid results in two phenotypically distinct inherited metabolic disorders, Salla disease and infantile sialic acid storage disease. Clinical and biochemical findings in both diseases are reviewed. Recent studies indicate that sialic acid storage is a consequence of defective function of a lysosomal membrane transport system specific for sialic acid and some other acidic monosaccharides.
Subject(s)
Lysosomal Storage Diseases/metabolism , Proteins/physiology , Sialic Acids/metabolism , Adult , Animals , Biological Transport, Active , Finland/epidemiology , Heterozygote , Humans , Infant , Lysosomal Storage Diseases/classification , Lysosomal Storage Diseases/epidemiology , Lysosomal Storage Diseases/pathology , N-Acetylneuraminic Acid , Phenotype , Proteins/genetics , RatsABSTRACT
ASA-NeuAc2en, a photoreactive arylazide derivative of sialic acid, is shown to be a powerful competitive inhibitor of lysosomal neuraminidase from bovine testis (Ki approximately 21 microM). Photoaffinity labeling and partial purification of preparations containing this lysosomal neuraminidase activity result in specifically and non-specifically labeled polypeptides. Only labeling in a 55 kDa polypeptide is found to be specific, since it could be prevented by the competitive neuraminidase inhibitor NeuAc2en. We conclude that the 55 kDa polypeptide in the bovine testis beta-galactosidase/neuraminidase/protective protein complex contains the catalytic site of neuraminidase.